The Relative Strength (RS) Rating for Immunocore Holdings ADR entered a new percentile Tuesday, with a rise from 80 to 87.
Hone Your Stock-Picking Skills By Focusing On These Factors
This unique rating tracks technical performance by using a 1 (worst) to 99 (best) score that indicates how a stock's price performance over the last 52 weeks matches up against the rest of the market.
Over 100 years of market history shows that the stocks that go on to make the biggest gains typically have an RS Rating of above 80 as they launch their biggest runs.
Immunocore Holdings ADR is not currently near a potential buy zone. See if the stock goes on to build a base that could spark a new run.
Immunocore Holdings ADR reported 0% earnings growth last quarter, while sales growth came in at 36%.
The company holds the No. 28 rank among its peers in the Medical-Biomed/Biotech industry group. Exelixis, Catalyst Pharmaceuticals and ADMA Biologics are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
